Recent Company News

• 01:14 AM ET Jul 08, 2026
  

  Addex Therapeutics announces publication of research highlighting therapeutic potential of mGlu7 modulation in regulating sleep and wakefulness (CHF 0.04, 0.00)

• 02:58 AM ET Jun 25, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:09 AM ET Jun 25, 2026
  

  Addex Therapeutics reports Q1 net income (CHF1.7M) vs year-ago (CHF1.5M) (CHF 0.04, 0.00)

• 04:40 AM ET Apr 21, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:15 AM ET Apr 30, 2026
  

  Addex Therapeutics reports Q4 net loss (CHF6.7M) vs year-ago CHF7.1M (CHF 0.05, 0.00)

• 01:20 AM ET Apr 23, 2026
  

  Addex spin-out company Neurosterix on track to complete Phase 1 clinical study of NTX-253 for schizophrenia in Q2 2026 (CHF 0.05, 0.00)